4 completed, 2 active not recruiting, 2 unknown, 1 withdrawn. 9 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Active not recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Unknown 2, Active not recruiting 1 |
Follow Mycophenolate Mofetil (MMF): new trials by email Literature Review of Mycophenolate Mofetil (MMF) trials Research Report on Mycophenolate Mofetil (MMF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT Fludarabine, Busulfan, Cyclophosphamide - Non-Hodgkin's Lymphoma, Acute Leukemia in Remission | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2017-01-31 | 2021-09-16 |
| CCFZ533X2201 - PoC Study in de Novo Renal Transplantation CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF) - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2015-02-05 | 2021-09-28 |
| Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress mycophenolate mofetil (MMF), Placebo - Psychological Stress, Hypertension, Renal | Phase 1 / Phase 2 | Unknown | Augusta University | 50 | 2014-04-22 | 2019-06-20 |
| Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection Anti-Thymocyte Globulin, TOL101, Steroids - End Stage Renal Disease, Renal Transplant | Phase 1 / Phase 2 | Unknown | Tolera Therapeutics, Inc | 85 | 2010-07-01 | 2013-06-11 |
| Infusion of Expanded Cord Blood T Cells Total Body Irradiation (TBI), Melphalan, Thiotepa - Stem Cell Transplantation, Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2009-09-01 | 2012-10-11 | |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 27 | 2006-01-01 | 2025-05-04 |
| Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation Daclizumab, Mycophenolate mofetil (MMF), Prednisone - Kidney Diseases, Kidney Transplantation | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 130 | 2004-03-01 | 2016-11-29 |
Myelodysplastic Syndromes (3) · Graft vs Host Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Non-Hodgkin (2) · Blast Crisis (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Hypertension, Renal (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1)
Augusta University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · Tolera Therapeutics, Inc (1) · University of Michigan Rogel Cancer Center (1)
United States (8) · Brazil (1) · Germany (1) · Netherlands (1)
Everett Meyer, MD,PhD (1) · Gregory A Harshfield, PhD (1) · Laura L. Worth, MD, PHD (1) · Minnie Sarwal, MD, PhD (1) · Neal Flomenberg, MD (1) · Nelli Bejanyan, M.D. (1) · Oscar Salvatierra, MD (1) · Stuart Flechner, MD (1) · Sung W Choi, MD, MS (1)
PMID 21868572, PMID 22694733, PMID 22694755, PMID 23009139, PMID 33635333, PMID 42784255
UL1TR002240 (1)